Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by L. L. Ilag
Total Records ( 2 ) for L. L. Ilag
  A. R. Chacra , M. Kipnes , L. L. Ilag , S. Sarwat , J. Giaconia and J. Chan
  Aims  The efficacy of two basal insulins, insulin lispro protamine suspension (ILPS) and insulin detemir, was compared in basal-bolus regimens in Type 1 diabetes.

Methods  In this 32-week, multinational, parallel-group, randomized, controlled trial, adult patients with Type 1 diabetes received ILPS or insulin detemir, injected twice daily (before breakfast and bedtime) and prandial insulin lispro three times daily. The primary outcome was change in glycated haemoglobin (HbA1c) from baseline to endpoint.

Results  Least squares mean (±se) changes in HbA1c were similar between groups, meeting non-inferiority (margin, 0.4%): −0.69 ± 0.07% for ILPS and −0.59 ± 0.07% for insulin detemir [between-treatment difference −0.10%; 95% confidence interval (CI) −0.29, 0.10]. Standard deviation of fasting blood glucose was similar (non-inferiority margin 0.8 mmol/l): 2.74 ± 0.14 mmol/l for ILPS and 2.38 ± 0.14 mmol/l for insulin detemir (CI −0.03, 0.75). Patients on ILPS gained more weight (1.59 ± 0.23 kg vs. 0.62 ± 0.24 kg; CI 0.34, 1.60; margin 1.5 kg). Weight-adjusted daily total and prandial insulin doses were lower for ILPS (prandial insulin, 0.38 ± 0.01 U/kg/day for ILPS, 0.44 ± 0.01 U/kg/day for insulin detemir; P = 0.004); daily basal insulin dose was similar. All hypoglycaemia incidence and rate and nocturnal hypoglycaemia incidence were similar between groups; nocturnal hypoglycaemia rate was lower for insulin detemir (mean ± sd 0.79 ± 1.23 for ILPS, 0.49 ± 0.85 for insulin detemir; P = 0.001). Severe hypoglycaemia rate was 0.03 ± 0.11 for ILPS and 0.02 ± 0.10 for insulin detemir (P = 0.37).

Conclusions  ILPS-treated patients with Type 1 diabetes achieved similar glycaemic control as insulin detemir-treated patients after 32 weeks. Glucose variability was similar. While weight gain and nocturnal hypoglycaemia rate were statistically higher with ILPS, the clinical relevance is unclear.

  S. Sarwat , L. L. Ilag , M. A. Carey , D. S. Shrom and R. J. Heine
  Aims  Self-monitoring of blood glucose (SMBG) is an important self-management tool for insulin-treated patients with Type 2 diabetes mellitus (T2DM). Its value in estimating glycaemic control in insulin-treated T2DM patients remains unclear. The relationship between glycated haemoglobin (HbA1c) and SMBG measures in T2DM patients treated with premixed insulin lispro mixtures or basal insulin glargine was examined.

Methods  HbA1c and plasma equivalent glucose (PGe) data derived from SMBG profiles were pooled from five randomized clinical trials of patients with T2DM on one or more oral glucose-lowering medication ± 0-2 insulin injections per day switching to insulin lispro mixtures (N = 317) or glargine (N = 306). Patients generated seven-point SMBG profiles three times in a 2-week period prior to each HbA1c measurement. Pearson's correlation coefficients (r) were calculated for PGe values and HbA1c. Receiver-operating characteristic (ROC) curves determined the ability of sets of PGe to estimate HbA1c (< or > 7.0%).

Results  Mean ± standard deviation age was 57.5 ± 9.5 years, body mass index 31.3 ± 5.6 kg/m2, 52.5% were male and HbA1c overall was 7.4 ± 1.0% at end-point. Among individual SMBG measures, r for HbA1c ranged from 0.34 to 0.49. For means of two or more PGe measures, r for HbA1c ranged from 0.51 to 0.59. Correlations were similar for either regimen. ROC curves were consistent with the correlation data.

Conclusions  These data provide patients and clinicians information on the relationship between HbA1c and SMBG measurements in patients with T2DM, and support the value of frequent blood glucose measurements for assessing overall glycaemic control.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility